Increased Response to Immune Checkpoint Inhibitors with Dietary Methionine Restriction in a Colorectal Cancer Model
- PMID: 37760436
- PMCID: PMC10526448
- DOI: 10.3390/cancers15184467
Increased Response to Immune Checkpoint Inhibitors with Dietary Methionine Restriction in a Colorectal Cancer Model
Abstract
Dietary methionine restriction (MR), defined as a reduction of methionine intake by around 80%, has been shown to reproducibly decrease tumor growth and synergize with cancer therapies. In this study, we combined DMR with immune checkpoint inhibitors (ICIs) in a model of colon adenocarcinoma. In vitro, we observed that MR increased the expression of MHC-I and PD-L1 in both mouse and human colorectal cancer cells. We also saw an increase in the gene expression of STING, a known inducer of type I interferon signaling. Inhibition of the cGAS-STING pathway, pharmacologically or with siRNA, blunted the increase in MHC-I and PD-L1 surface and gene expression following MR. This indicated that the cGAS-STING pathway, and interferon in general, played a role in the immune response to MR. We then combined dietary MR with ICIs targeting CTLA-4 and PD-1 in an MC38 colorectal cancer tumor model developed in immunocompetent C57BL/6 mice. The combination treatment was five times more effective at reducing the tumor size than ICIs alone in male mice. We noted sex differences in the response to dietary MR, with males showing a greater response than females. Finally, we observed an increase in membrane staining for the PD-L1 protein in MC38 tumors from animals who were fed an MR diet. MHC-I was highly expressed in all tumors and showed no expression difference when comparing tumors from control and MR-treated mice. These results indicated that MR increased PD-L1 expression both in vitro and in vivo and improved the response to ICIs in mice.
Keywords: PD-L1; STING; colorectal; immune checkpoint inhibitors; methionine restriction.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
Update of
-
Increased response to immune checkpoint inhibitors with dietary methionine restriction.bioRxiv [Preprint]. 2023 Apr 6:2023.04.05.535695. doi: 10.1101/2023.04.05.535695. bioRxiv. 2023. Update in: Cancers (Basel). 2023 Sep 07;15(18):4467. doi: 10.3390/cancers15184467. PMID: 37066240 Free PMC article. Updated. Preprint.
Similar articles
-
Increased response to immune checkpoint inhibitors with dietary methionine restriction.bioRxiv [Preprint]. 2023 Apr 6:2023.04.05.535695. doi: 10.1101/2023.04.05.535695. bioRxiv. 2023. Update in: Cancers (Basel). 2023 Sep 07;15(18):4467. doi: 10.3390/cancers15184467. PMID: 37066240 Free PMC article. Updated. Preprint.
-
Combining radiation and the ATR inhibitor berzosertib activates STING signaling and enhances immunotherapy via inhibiting SHP1 function in colorectal cancer.Cancer Commun (Lond). 2023 Apr;43(4):435-454. doi: 10.1002/cac2.12412. Epub 2023 Feb 28. Cancer Commun (Lond). 2023. PMID: 36855844 Free PMC article.
-
Radiation-induced PD-L1 expression in tumor and its microenvironment facilitates cancer-immune escape: a narrative review.Ann Transl Med. 2022 Dec;10(24):1406. doi: 10.21037/atm-22-6049. Ann Transl Med. 2022. PMID: 36660640 Free PMC article. Review.
-
The epigenetic immunomodulator, HBI-8000, enhances the response and reverses resistance to checkpoint inhibitors.BMC Cancer. 2021 Aug 30;21(1):969. doi: 10.1186/s12885-021-08702-x. BMC Cancer. 2021. PMID: 34461854 Free PMC article.
-
Current Understanding of the Mechanisms Underlying Immune Evasion From PD-1/PD-L1 Immune Checkpoint Blockade in Head and Neck Cancer.Front Oncol. 2020 Feb 28;10:268. doi: 10.3389/fonc.2020.00268. eCollection 2020. Front Oncol. 2020. PMID: 32185135 Free PMC article. Review.
Cited by
-
Rescue of Methionine Dependence by Cobalamin in a Human Colorectal Cancer Cell Line.Nutrients. 2024 Mar 28;16(7):997. doi: 10.3390/nu16070997. Nutrients. 2024. PMID: 38613029 Free PMC article.
-
Dietary factors and their influence on immunotherapy strategies in oncology: a comprehensive review.Cell Death Dis. 2024 Apr 9;15(4):254. doi: 10.1038/s41419-024-06641-6. Cell Death Dis. 2024. PMID: 38594256 Free PMC article. Review.
-
Dietary methionine restriction in cancer development and antitumor immunity.Trends Endocrinol Metab. 2024 May;35(5):400-412. doi: 10.1016/j.tem.2024.01.009. Epub 2024 Feb 20. Trends Endocrinol Metab. 2024. PMID: 38383161 Review.
-
Circadian lifestyle determinants of immune checkpoint inhibitor efficacy.Front Oncol. 2023 Dec 4;13:1284089. doi: 10.3389/fonc.2023.1284089. eCollection 2023. Front Oncol. 2023. PMID: 38111535 Free PMC article. Review.
-
Endogenous Metabolites and Genome Instability in Aging and Disease.Chem Res Toxicol. 2023 Dec 18;36(12):1830-1833. doi: 10.1021/acs.chemrestox.3c00288. Epub 2023 Nov 10. Chem Res Toxicol. 2023. PMID: 37947799 Free PMC article. Review.
References
-
- Malloy V.L., Krajcik R.A., Bailey S.J., Hristopoulos G., Plummer J.D., Orentreich N. Methionine Restriction Decreases Visceral Fat Mass and Preserves Insulin Action in Aging Male Fischer 344 Rats Independent of Energy Restriction. Aging Cell. 2006;5:305–314. doi: 10.1111/j.1474-9726.2006.00220.x. - DOI - PubMed
-
- Lees E.K., Król E., Grant L., Shearer K., Wyse C., Moncur E., Bykowska A.S., Mody N., Gettys T.W., Delibegovic M. Methionine Restriction Restores a Younger Metabolic Phenotype in Adult Mice with Alterations in Fibroblast Growth Factor 21. Aging Cell. 2014;13:817–827. doi: 10.1111/acel.12238. - DOI - PMC - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials